122 related articles for article (PubMed ID: 29194036)
1. Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients: a systematic review.
Kjaer IM; Bechmann T; Brandslund I; Madsen JS
Clin Chem Lab Med; 2018 Apr; 56(5):688-701. PubMed ID: 29194036
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of serum levels of EGFR and EGFR ligands in early-stage breast cancer.
Kjær IM; Olsen DA; Brandslund I; Bechmann T; Jakobsen EH; Bogh SB; Madsen JS
Sci Rep; 2020 Oct; 10(1):16558. PubMed ID: 33024132
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer.
Tas F; Bilgin E; Karabulut S; Duranyildiz D
Cytokine; 2015 Jan; 71(1):66-70. PubMed ID: 25259789
[TBL] [Abstract][Full Text] [Related]
5. Dysregulated EGFR pathway in serum in early-stage breast cancer patients: A case control study.
Kjær IM; Olsen DA; Brandslund I; Bechmann T; Jakobsen EH; Bogh SB; Madsen JS
Sci Rep; 2020 Apr; 10(1):6714. PubMed ID: 32317675
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
Jiang R; Wang X; Li K
Oncotarget; 2016 May; 7(18):26823-36. PubMed ID: 27072585
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
8. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
Gasparini G; Boracchi P; Bevilacqua P; Mezzetti M; Pozza F; Weidner N
Breast Cancer Res Treat; 1994 Jan; 29(1):59-71. PubMed ID: 7912568
[TBL] [Abstract][Full Text] [Related]
9. Discovery and validation of breast cancer early detection biomarkers in preclinical samples.
Li CI
Horm Cancer; 2011 Apr; 2(2):125-31. PubMed ID: 21761335
[TBL] [Abstract][Full Text] [Related]
10. The importance of EGFR as a biomarker in molecular apocrine breast cancer.
Liu X; Feng C; Liu J; Liu J; Li C; Xu C; Niu Y
Hum Pathol; 2018 Jul; 77():1-10. PubMed ID: 29409930
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Surgery; 2003 Feb; 133(2):219-21. PubMed ID: 12605184
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.
Lo Nigro C; Ricci V; Vivenza D; Granetto C; Fabozzi T; Miraglio E; Merlano MC
World J Gastroenterol; 2016 Aug; 22(30):6944-54. PubMed ID: 27570430
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer.
Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
Breast Cancer Res Treat; 2002 Jan; 71(1):67-75. PubMed ID: 11859875
[TBL] [Abstract][Full Text] [Related]
14. Prediction of breast cancer metastasis risk using circulating tumor markers: A follow-up study.
Cetintas S; Tezcan G; Tunca B; Egeli U; Gokgoz MS; Cecener G
Bosn J Basic Med Sci; 2019 May; 19(2):172-179. PubMed ID: 30242807
[TBL] [Abstract][Full Text] [Related]
15. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
16. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4.
Lodge AJ; Anderson JJ; Gullick WJ; Haugk B; Leonard RC; Angus B
J Clin Pathol; 2003 Apr; 56(4):300-4. PubMed ID: 12663644
[TBL] [Abstract][Full Text] [Related]
17. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic value of EGFR in invasive breast cancer.
Quintela I; Corte MD; Allende MT; Vazquez J; Rodríguez JC; Bongera M; Lamelas M; Gonzalez LO; Vega A; García-Muñiz JL; Astudillo A; Vizoso F
Oncol Rep; 2005 Dec; 14(6):1655-63. PubMed ID: 16273272
[TBL] [Abstract][Full Text] [Related]
19. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
DiGiovanna MP; Stern DF; Edgerton SM; Whalen SG; Moore D; Thor AD
J Clin Oncol; 2005 Feb; 23(6):1152-60. PubMed ID: 15718311
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
